Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
Study Details
Study Description
Brief Summary
The purpose of this trial is to determine whether BIBF 1120 can be safely combined with pegylated liposomal doxorubicin (phase I), and to determine the clinical activity of the combination in patients with platinum-resistant ovarian cancer (phase II).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
OUTLINE: This is a phase I/II multi-center study.
Phase I:
All patients will receive a fixed dose of pegylated liposomal doxorubicin (Doxil) of 40 mg/m2 administered IV every 28 days. The dose of BIBF 1120 will be escalated in successive cohorts of patients. A maximum of 12 cycles of combined therapy will be administered corresponding to maximum cumulative dose of PLD of 480 mg/m2. Continuation therapy with single agent BIBF 1120 may continue for selected patients.
The escalation phase will follow the standard 3+3 design. Patients will be accrued to each dose level in cohorts of up to 3-6 evaluable patients. Escalation will continue until a DLT is observed, the highest dose level is reached, or medical judgment indicates. An expansion cohort of 3 to 6 patients will be treated at the MTD (or highest dose level if the MTD is not reached), in order to ensure tolerability of the regimen prior to initiating the Phase II component of the study.
Phase II:
Patients will receive a fixed dose of pegylated liposomal doxorubicin (Doxil) of 40 mg/m2 administered IV every 28 days. Patients will be treated at either dose Level +2 or the MTD dose level of BIBF 1120 as defined by the Phase I cohort. Each cycle will be 28 days. Patients will continue treatment with the combination therapy for a total of up to 12 cycles.
ECOG Performance Status 0-1
Life Expectancy: Not specified
Hematopoietic:
-
Absolute neutrophil count ≥ 1500 cells/mm3
-
White cell blood count ≥ 3000 cells/mm3
-
Hemoglobin ≥ 9.0 g/dL (can be post-transfusion)
-
Platelets ≥ 100,000/mm3 (can not be post-transfusion)
Hepatic:
-
Aspartate aminotransferase and alanine aminotransferase less than or equal to 2.5 times upper limit of normal (ULN)
-
Total serum bilirubin ≤ 1.5 times ULN
-
Alkaline phosphatase ≤ 2.5 times ULN
Renal:
- Creatinine levels ≤ 1.5 times ULN
Cardiovascular:
-
Baseline left ventricular ejection fraction greater than 50%
-
International Normalized ratio(INR) ≤ 1.5 times ULN, except patients on stable doses of coumadin or low molecular weight heparin NOTE: Patients on stable doses of coumadin or low molecular weight heparin are eligible if anticoagulant doses have been stable and no bleeding complications were recorded.
-
Partial thromboplastin time (PTT) ≤1.5 times ULN
This study was terminated due to drug availability and Phase II never opened.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Doxil + BIBF 1120
|
Drug: Doxil (Pegylated Liposomal Doxorubicin)
Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle
Drug: BIBF 1120
Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid
Phase II: MTD orally, bid, day 2 of 28-day cycle
|
Outcome Measures
Primary Outcome Measures
- Phase I: Safety and Toxicity of Treatment Regimen [3 months]
To find the maximum tolerated dose (MTD) to be used during the Phase II trial and evaluate the safety and toxicity of the combination BIBF 1120 plus PLD in patients with recurrent or resistant epithelial ovarian or endometrial cancer.
- Phase II: Objective Response Rate [12 months]
To assess response rate (objective response) in patients with recurrent or resistant epithelial ovarian cancer treated with BIBF 1120 plus PLD.
Secondary Outcome Measures
- Phase I and II: Progression-Free Survival [12 months]
To determine the progression-free survival of Phase I and II patients with recurrent or resistant epithelial ovarian cancer treated with BIBF 1120 plus PLD.
- Phase I and II: Clinical Benefit [12 months]
To determine the rate of clinical benefit for Phase I and II defined as: the number of patients experiencing an objective response or a CA125 response, in the absence of disease progression by clinical or radiographic criteria sustained stable disease ≥ 3 months by clinical and radiographic criteria
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Platinum-resistant (recurrence within 6 months of a platinum-containing regimen) or platinum refractory (progression while on platinum) disease.
-
Measurable disease as defined by RECIST v1.1 criteria on screening testing
-
Be ≥18 years of age at the time of providing written informed consent for participation.
-
Give written, informed consent for participation in the protocol.
-
Must consent to correlative blood sample collections.
-
Be at least 4 weeks from last treatment to allow recovery from prior toxicity to a Grade 1 or less.
-
The following exceptions are allowed: hormonal therapy - 1 week wash-out; radiation therapy - 3 week wash-out; weekly chemotherapy - 3 week wash-out
-
Patients coming off experimental therapy with biological agents with long half lives (e.g., antibodies) not expected to cause myelotoxicity should be off treatment for at least 4 weeks.
-
Negative serum pregnancy test within 14 days prior to the study entry and be practicing an effective form of contraception if hysterectomy and/or oophorectomy was not part of the prior treatment
Exclusion Criteria:
-
Prior therapy with pegylated liposomal doxorubicin or doxorubicin.
-
Prior therapy with BIBF 1120.
-
Prior anti-angiogenic therapy with tyrosine kinase inhibitors (e.g. sorafenib, sunitinib, others). Note: Prior therapy with bevacizumab is allowed, provided that at least 3 months have elapsed since the last dose of bevacizumab.
-
Grade 2 or greater neuropathy, at time of registration.
-
Active cancer within the last 5 years, with the exception of superficial skin cancer (basal cell or squamous cell skin carcinoma), carcinoma in situ of the cervix, Stage I endometrial cancer with less than 50% invasion of the myometrium, or other adequately treated Stage I or II cancer in complete remission.
-
Presence of active infection requiring antibiotic treatment, at time of registration.
-
Presence of uncontrolled serious medical condition or psychiatric illness as determined by the treating physician, at time of registration.
-
Known history of immune deficiency and be receiving combination anti-retroviral therapy
-
Known or clinically manifest brain metastases, as progressive neurologic dysfunction may develop, that would confound the evaluation of neurologic and other adverse events.
-
Presence of gastrointestinal disorders or abnormalities that would influence the absorption of the study drug.
-
Presence of uncontrolled hypertension, arrhythmia, congestive heart failure or angina, at time of registration. Patients who have had a myocardial infarction or cardiac surgery should be at least 6 months from the event and free of active symptoms.
-
Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infection disease or laboratory abnormality that may increase the risk associated with study participation or study drug administration.
-
Major injuries within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period.
-
History of clinically significant hemorrhagic or thromboembolic event in the past 6 months
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | United States | 46202 |
| 2 | University of Wisconsin | Madison | Wisconsin | United States | 53705 |
Sponsors and Collaborators
- Hoosier Cancer Research Network
- Boehringer Ingelheim
Investigators
- Principal Investigator: Daniela Matei, M.D., Hoosier Cancer Research Network
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- GYN10-149